Table 1 Clinical variables for patients with resectable gastric cancer 2007–2016 receiving neoadjuvant chemotherapy (NAC). Response was evaluated by TNM downstaging at repeated CT-scans, n = 169 (%)
Total | Response | Stable disease | Progression | p value* | |
|---|---|---|---|---|---|
Age category | 0.55 | ||||
< 60 years | 48 (28%) | 19 (40%) | 23 (48%) | 6 (13%) | |
60–70 years | 76 (45%) | 34 (45%) | 38 (50%) | 4 (5%) | |
> 70 years | 45 (27%) | 20 (44%) | 23 (51%) | 2 (4%) | |
Gender | 0.47 | ||||
Male | 118 (70%) | 54 (46%) | 55 (47%) | 9 (8%) | |
Female | 51 (30%) | 19 (37%) | 29 (57%) | 3 (6%) | |
Tumour location | 0.03 | ||||
Cardia | 65 (38%) | 32(49%) | 29 (45%) | 4 (6%) | |
Corpus | 32 (19%) | 19 (59%) | 12 (38%) | 1 (3%) | |
Antrum | 51 (30%) | 19 (37%) | 30 (59%) | 2 (4%) | |
Diffuse | 21 (12%) | 3 (14%) | 13 (62%) | 5 (24%) | |
Disease stage** | < 0.01 | ||||
Stage 1b | 14 (8%) | 5 (36%) | 9 (64%) | 0 | |
Stage IIa/b | 54 (32%) | 15 (28%) | 39 (72%) | 0 | |
Stage IIIa | 32 (19%) | 18 (56%) | 13 (41%) | 1 (3%) | |
Stage IIIb | 42 (25%) | 20 (48%) | 17 (41%) | 5 (12%) | |
Stage IIIc | 27 (16%) | 15 (56%) | 6 (22%) | 6 (22%) | |
T-stage** | 0.04 | ||||
T2 | 22 (13%) | 11 (50%) | 11 (50%) | 0 | |
T3 | 33 (20%) | 11 (33%) | 22 (67%) | 0 | |
T4a/b | 114 (67%) | 51 (45%) | 51 (45%) | 12 (11%) | |
N-stage** | < 0.01 | ||||
N0 | 53 (31%) | 10 (19%) | 41 (77%) | 2 (4%) | |
N1 | 50 (30%) | 24 (48%) | 24 (48%) | 2 (4%) | |
N2 | 51(30%) | 33 (65%) | 15 (29%) | 3 (6%) | |
N3 | 15(9%) | 6 (40%) | 4 (27%) | 5 (33%) | |
Lauren classification*** | 0.79 | ||||
Diffuse | 68 (40%) | 26 (38%) | 37 (54%) | 5 (7%) | |
Intestinal | 73 (43%) | 33 (45%) | 34 (47%) | 6 (8%) | |
Mixed | 27 (16%) | 14 (52%) | 12 (44%) | 1 (4%) | |
Number of cycles delivered | 0.41 | ||||
< 3 | 24 (14%) | 12 (50%) | 11 (46%) | 1 (4%) | |
3 | 145 (86%) | 61 (42%) | 73 (50%) | 11 (8%) |